They have put a financing plan in place that will allow minimal dilution. They may be planning on a partner, or they may be planning on more government grants.
Looks like they have at least three options to go forward.
Also note - the trials will be much simpler and cost less than cancer and other disease trials. No issues of toxicity and from what we've seen so far it seems that the results will be relatively unambiguous.
Market Data 
Markets 
AI
